ArticleFrontiers in medicine2026
Polymyxin B-induced acute kidney injury in a burn patient: a case report and pharmaceutical care.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polymyxin B is increasingly used against multidrug-resistant Gram-negative bacteria but carries a risk of acute kidney injury (AKI). Burn patients are particularly vulnerable. Case summary: A 44-year-old male with 66% TBSA burns and sepsis received polymyxin B (50 mg q12h, then escalated to 100 mg q12h). Serum creatinine rose from 59 to 163 μmol/L within 3 days, meeting KDIGO AKI criteria. No other nephrotoxic agents were used. The Naranjo score was 5, indicating probable polymyxin B-induced AKI. After dose reduction to 50 mg q12h, renal function improved without discontinuing therapy. Conclusion: In burn patients, early renal function monitoring (within 3 days) and dose adjustment based on infection response and renal biomarkers are critical. Therapeutic drug monitoring is recommended when available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.